Jorge Daza
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jorge Daza has a total of 65 co-authors. Here are the top co-authors by number of shared publications:
- John P. Sfakianos
Icahn School of Medicine at Mount Sinai Hospital, New York, NY, USA
8 shared publications - Matthew D. Galsky
Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
6 shared publications - Adam M. Farkas
Icahn School of Medicine at Mount Sinai 1 Division of Hematology and Medical Oncology, Tisch Cancer Institute New York, New York
5 shared publications - Bishoy Morris Faltas
Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY 10021, USA
5 shared publications - David J. Mulholland
Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York
5 shared publications - Haocheng Yu
Sema4, Stamford, Connecticut
5 shared publications
Latest Publications
- 7 July 2023
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 41 (10) , 429.e1-429.e7
Does testosterone replacement therapy increase the risk of conversion to treatment in patients with prostate cancer on active surveillance?
- 7 July 2023
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 41 (10) , 429.e1-429.e7
Does testosterone replacement therapy increase the risk of conversion to treatment in patients with prostate cancer on active surveillance?
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Data from Tumor-Infiltrating Myeloid Cells Confer De Novo Resistance to PD-L1 Blockade through EMT–Stromal and Tgfβ-Dependent Mechanisms
Most bladder cancers are poorly responsive to immune checkpoint blockade (ICB). With the need to define mechanisms of de novo resistance, including contributions from the tumor microenvironment (TME), we used single-cell transcriptional profiling to map tumor-infiltrating lymphocytic and myeloid cells in 10 human bladder tumors obtained from patients with a history of smoking either with or without previous ICB. Human datasets were qualitatively compared with single cell datasets from the BBN carcinogen-induced mouse model of bladder cancer, which was poorly responsive to PD-L1 blockade. We applied an established signature of acquired ICB resistance to these human and murine datasets to reveal conservation in EMT and TGFβ ICB resistance signatures between human–mouse stromal and myeloid cells. Using TCGA transcriptional datasets and deconvolution analysis, we showed that patients with a history of smoking and bladder tumors high in M2 macrophage tumor content had a significantly worse survival outcome compared with nonsmokers who were M2 high. Similarly, BBN-induced tumors were high in M2 macrophage content and contained exhausted T–NK cells, thereby modeling the identified TCGA patient subpopulation. The combined targeting of TGFβ + PD-L1 reverted immune cell exclusion and resulted in increased survival and delayed BBN-induced tumor progression. Together, these data support a coordinated role for stromal and myeloid cell populations in promoting de novo resistance to PD-L1 blockade, particularly in patients with a history of smoking.Significance:Most patients with bladder cancer do not respond to ICB targeting of the PD-L1 signaling axis. Our modeling applied a de novo resistance signature to show that tumor-infiltrating myeloid cells promote poor treatment response in a TGFβ-dependent mechanism.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Tumor-Infiltrating Myeloid Cells Confer De Novo Resistance to PD-L1 Blockade through EMT–Stromal and Tgfβ-Dependent Mechanisms
Most bladder cancers are poorly responsive to immune checkpoint blockade (ICB). With the need to define mechanisms of de novo resistance, including contributions from the tumor microenvironment (TME), we used single-cell transcriptional profiling to map tumor-infiltrating lymphocytic and myeloid cells in 10 human bladder tumors obtained from patients with a history of smoking either with or without previous ICB. Human datasets were qualitatively compared with single cell datasets from the BBN carcinogen-induced mouse model of bladder cancer, which was poorly responsive to PD-L1 blockade. We applied an established signature of acquired ICB resistance to these human and murine datasets to reveal conservation in EMT and TGFβ ICB resistance signatures between human–mouse stromal and myeloid cells. Using TCGA transcriptional datasets and deconvolution analysis, we showed that patients with a history of smoking and bladder tumors high in M2 macrophage tumor content had a significantly worse survival outcome compared with nonsmokers who were M2 high. Similarly, BBN-induced tumors were high in M2 macrophage content and contained exhausted T–NK cells, thereby modeling the identified TCGA patient subpopulation. The combined targeting of TGFβ + PD-L1 reverted immune cell exclusion and resulted in increased survival and delayed BBN-induced tumor progression. Together, these data support a coordinated role for stromal and myeloid cell populations in promoting de novo resistance to PD-L1 blockade, particularly in patients with a history of smoking.Significance:Most patients with bladder cancer do not respond to ICB targeting of the PD-L1 signaling axis. Our modeling applied a de novo resistance signature to show that tumor-infiltrating myeloid cells promote poor treatment response in a TGFβ-dependent mechanism.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Data from Tumor-Infiltrating Myeloid Cells Confer De Novo Resistance to PD-L1 Blockade through EMT–Stromal and Tgfβ-Dependent Mechanisms
Most bladder cancers are poorly responsive to immune checkpoint blockade (ICB). With the need to define mechanisms of de novo resistance, including contributions from the tumor microenvironment (TME), we used single-cell transcriptional profiling to map tumor-infiltrating lymphocytic and myeloid cells in 10 human bladder tumors obtained from patients with a history of smoking either with or without previous ICB. Human datasets were qualitatively compared with single cell datasets from the BBN carcinogen-induced mouse model of bladder cancer, which was poorly responsive to PD-L1 blockade. We applied an established signature of acquired ICB resistance to these human and murine datasets to reveal conservation in EMT and TGFβ ICB resistance signatures between human–mouse stromal and myeloid cells. Using TCGA transcriptional datasets and deconvolution analysis, we showed that patients with a history of smoking and bladder tumors high in M2 macrophage tumor content had a significantly worse survival outcome compared with nonsmokers who were M2 high. Similarly, BBN-induced tumors were high in M2 macrophage content and contained exhausted T–NK cells, thereby modeling the identified TCGA patient subpopulation. The combined targeting of TGFβ + PD-L1 reverted immune cell exclusion and resulted in increased survival and delayed BBN-induced tumor progression. Together, these data support a coordinated role for stromal and myeloid cell populations in promoting de novo resistance to PD-L1 blockade, particularly in patients with a history of smoking.Significance:Most patients with bladder cancer do not respond to ICB targeting of the PD-L1 signaling axis. Our modeling applied a de novo resistance signature to show that tumor-infiltrating myeloid cells promote poor treatment response in a TGFβ-dependent mechanism.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Tumor-Infiltrating Myeloid Cells Confer De Novo Resistance to PD-L1 Blockade through EMT–Stromal and Tgfβ-Dependent Mechanisms
Most bladder cancers are poorly responsive to immune checkpoint blockade (ICB). With the need to define mechanisms of de novo resistance, including contributions from the tumor microenvironment (TME), we used single-cell transcriptional profiling to map tumor-infiltrating lymphocytic and myeloid cells in 10 human bladder tumors obtained from patients with a history of smoking either with or without previous ICB. Human datasets were qualitatively compared with single cell datasets from the BBN carcinogen-induced mouse model of bladder cancer, which was poorly responsive to PD-L1 blockade. We applied an established signature of acquired ICB resistance to these human and murine datasets to reveal conservation in EMT and TGFβ ICB resistance signatures between human–mouse stromal and myeloid cells. Using TCGA transcriptional datasets and deconvolution analysis, we showed that patients with a history of smoking and bladder tumors high in M2 macrophage tumor content had a significantly worse survival outcome compared with nonsmokers who were M2 high. Similarly, BBN-induced tumors were high in M2 macrophage content and contained exhausted T–NK cells, thereby modeling the identified TCGA patient subpopulation. The combined targeting of TGFβ + PD-L1 reverted immune cell exclusion and resulted in increased survival and delayed BBN-induced tumor progression. Together, these data support a coordinated role for stromal and myeloid cell populations in promoting de novo resistance to PD-L1 blockade, particularly in patients with a history of smoking.Significance:Most patients with bladder cancer do not respond to ICB targeting of the PD-L1 signaling axis. Our modeling applied a de novo resistance signature to show that tumor-infiltrating myeloid cells promote poor treatment response in a TGFβ-dependent mechanism.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Tumor-Infiltrating Myeloid Cells Confer De Novo Resistance to PD-L1 Blockade through EMT–Stromal and Tgfβ-Dependent Mechanisms
Supplementary Data from Tumor-Infiltrating Myeloid Cells Confer De Novo Resistance to PD-L1 Blockade through EMT–Stromal and Tgfβ-Dependent Mechanisms
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Tumor-Infiltrating Myeloid Cells Confer De Novo Resistance to PD-L1 Blockade through EMT–Stromal and Tgfβ-Dependent Mechanisms
Supplementary Data from Tumor-Infiltrating Myeloid Cells Confer De Novo Resistance to PD-L1 Blockade through EMT–Stromal and Tgfβ-Dependent Mechanisms
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Tumor-Infiltrating Myeloid Cells Confer De Novo Resistance to PD-L1 Blockade through EMT–Stromal and Tgfβ-Dependent Mechanisms
Supplementary Data from Tumor-Infiltrating Myeloid Cells Confer De Novo Resistance to PD-L1 Blockade through EMT–Stromal and Tgfβ-Dependent Mechanisms
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Tumor-Infiltrating Myeloid Cells Confer De Novo Resistance to PD-L1 Blockade through EMT–Stromal and Tgfβ-Dependent Mechanisms
Supplementary Data from Tumor-Infiltrating Myeloid Cells Confer De Novo Resistance to PD-L1 Blockade through EMT–Stromal and Tgfβ-Dependent Mechanisms
- 21 March 2023
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 41 (5) , 256.e9-256.e15
Development of a predictive model for recurrence-free survival in pTa low-grade bladder cancer
- 21 March 2023
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 41 (5) , 256.e9-256.e15
Development of a predictive model for recurrence-free survival in pTa low-grade bladder cancer
- 7 March 2023
- Published by Wiley in BJU International
- Vol. 132 (1) , 75-83
Urine supernatant reveals a signature that predicts survival in clear‐cell renal cell carcinoma
Objective: To profile the cell‐free urine supernatant and plasma of a small cohort of clear‐cell renal cell carcinoma (ccRCC) patients by measuring the relative concentrations of 92 proteins related to inflammation. Using The Cancer Genome Atlas (TCGA), we then performed a targeted mRNA analysis of genes encoding the above proteins and defined their effects on overall survival (OS). Subjects/patients and Methods: Samples were collected prospectively from ccRCC patients. A multiplex proximity extension assay was used to measure the concentrations of 92 inflammation‐related proteins in cell‐free urine supernatants and plasma. Transcriptomic and clinical information from ccRCC patients was obtained from TCGA. Unsupervised clustering and differential protein expression analyses were performed on protein concentration data. Targeted mRNA analysis on genes encoding significant differentially expressed proteins was performed using TCGA. Backward stepwise regression analyses were used to build a nomogram. The performance of the nomogram and clinical benefit was assessed by discrimination and calibration, and a decision curve analysis, respectively. Results: Unsupervised clustering analysis revealed inflammatory signatures in the cell‐free urine supernatant of ccRCC patients. Backward stepwise regressions using TCGA data identified transcriptomic risk factors and risk groups associated with OS. A nomogram to predict 2‐year and 5‐year OS was developed using these risk factors. The decision curve analysis showed that our model was associated with a net benefit improvement compared to the treat‐all/none strategies. Conclusion: We defined four novel biomarkers using proteomic and transcriptomic data that distinguish severity of prognosis in ccRCC. We showed that these biomarkers can be used in a model to predict 2‐year and 5‐year OS in ccRCC across different tumour stages. This type of analysis, if validated in the future, provides non‐invasive prognostic information that could inform either management or surveillance strategies for patients.
- 7 March 2023
- Published by Wiley in BJU International
- Vol. 132 (1) , 75-83
Urine supernatant reveals a signature that predicts survival in clear‐cell renal cell carcinoma
Objective: To profile the cell‐free urine supernatant and plasma of a small cohort of clear‐cell renal cell carcinoma (ccRCC) patients by measuring the relative concentrations of 92 proteins related to inflammation. Using The Cancer Genome Atlas (TCGA), we then performed a targeted mRNA analysis of genes encoding the above proteins and defined their effects on overall survival (OS). Subjects/patients and Methods: Samples were collected prospectively from ccRCC patients. A multiplex proximity extension assay was used to measure the concentrations of 92 inflammation‐related proteins in cell‐free urine supernatants and plasma. Transcriptomic and clinical information from ccRCC patients was obtained from TCGA. Unsupervised clustering and differential protein expression analyses were performed on protein concentration data. Targeted mRNA analysis on genes encoding significant differentially expressed proteins was performed using TCGA. Backward stepwise regression analyses were used to build a nomogram. The performance of the nomogram and clinical benefit was assessed by discrimination and calibration, and a decision curve analysis, respectively. Results: Unsupervised clustering analysis revealed inflammatory signatures in the cell‐free urine supernatant of ccRCC patients. Backward stepwise regressions using TCGA data identified transcriptomic risk factors and risk groups associated with OS. A nomogram to predict 2‐year and 5‐year OS was developed using these risk factors. The decision curve analysis showed that our model was associated with a net benefit improvement compared to the treat‐all/none strategies. Conclusion: We defined four novel biomarkers using proteomic and transcriptomic data that distinguish severity of prognosis in ccRCC. We showed that these biomarkers can be used in a model to predict 2‐year and 5‐year OS in ccRCC across different tumour stages. This type of analysis, if validated in the future, provides non‐invasive prognostic information that could inform either management or surveillance strategies for patients.
- 21 September 2022
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 21 (11) , 1729-1741
Tumor-Infiltrating Myeloid Cells Confer De Novo Resistance to PD-L1 Blockade through EMT–Stromal and Tgfβ-Dependent Mechanisms
Most bladder cancers are poorly responsive to immune checkpoint blockade (ICB). With the need to define mechanisms of de novo resistance, including contributions from the tumor microenvironment (TME), we used single-cell transcriptional profiling to map tumor-infiltrating lymphocytic and myeloid cells in 10 human bladder tumors obtained from patients with a history of smoking either with or without previous ICB. Human datasets were qualitatively compared with single cell datasets from the BBN carcinogen-induced mouse model of bladder cancer, which was poorly responsive to PD-L1 blockade. We applied an established signature of acquired ICB resistance to these human and murine datasets to reveal conservation in EMT and TGFβ ICB resistance signatures between human–mouse stromal and myeloid cells. Using TCGA transcriptional datasets and deconvolution analysis, we showed that patients with a history of smoking and bladder tumors high in M2 macrophage tumor content had a significantly worse survival outcome compared with nonsmokers who were M2 high. Similarly, BBN-induced tumors were high in M2 macrophage content and contained exhausted T–NK cells, thereby modeling the identified TCGA patient subpopulation. The combined targeting of TGFβ + PD-L1 reverted immune cell exclusion and resulted in increased survival and delayed BBN-induced tumor progression. Together, these data support a coordinated role for stromal and myeloid cell populations in promoting de novo resistance to PD-L1 blockade, particularly in patients with a history of smoking. Significance: Most patients with bladder cancer do not respond to ICB targeting of the PD-L1 signaling axis. Our modeling applied a de novo resistance signature to show that tumor-infiltrating myeloid cells promote poor treatment response in a TGFβ-dependent mechanism.
- 21 September 2022
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 21 (11) , 1729-1741
Tumor-Infiltrating Myeloid Cells Confer De Novo Resistance to PD-L1 Blockade through EMT–Stromal and Tgfβ-Dependent Mechanisms
Most bladder cancers are poorly responsive to immune checkpoint blockade (ICB). With the need to define mechanisms of de novo resistance, including contributions from the tumor microenvironment (TME), we used single-cell transcriptional profiling to map tumor-infiltrating lymphocytic and myeloid cells in 10 human bladder tumors obtained from patients with a history of smoking either with or without previous ICB. Human datasets were qualitatively compared with single cell datasets from the BBN carcinogen-induced mouse model of bladder cancer, which was poorly responsive to PD-L1 blockade. We applied an established signature of acquired ICB resistance to these human and murine datasets to reveal conservation in EMT and TGFβ ICB resistance signatures between human–mouse stromal and myeloid cells. Using TCGA transcriptional datasets and deconvolution analysis, we showed that patients with a history of smoking and bladder tumors high in M2 macrophage tumor content had a significantly worse survival outcome compared with nonsmokers who were M2 high. Similarly, BBN-induced tumors were high in M2 macrophage content and contained exhausted T–NK cells, thereby modeling the identified TCGA patient subpopulation. The combined targeting of TGFβ + PD-L1 reverted immune cell exclusion and resulted in increased survival and delayed BBN-induced tumor progression. Together, these data support a coordinated role for stromal and myeloid cell populations in promoting de novo resistance to PD-L1 blockade, particularly in patients with a history of smoking. Significance: Most patients with bladder cancer do not respond to ICB targeting of the PD-L1 signaling axis. Our modeling applied a de novo resistance signature to show that tumor-infiltrating myeloid cells promote poor treatment response in a TGFβ-dependent mechanism.
- 18 November 2021
- Published by Springer Nature
- p. 441-455
Imaging and Interventional Diversion Techniques for Bladder and Ureteral Conditions
- 18 November 2021
- Published by Springer Nature
- p. 441-455
Imaging and Interventional Diversion Techniques for Bladder and Ureteral Conditions
- 1 March 2021
- Published by Edizioni Minerva Medica in Minerva Urology and Nephrology
- Vol. 73 (1) , 72-77
Identifying tumor-related risk factors for simultaneous adrenalectomy in patients with cT1-cT2 kidney cancer during robotic assisted laparoscopic radical nephrectomy
Article: Identifying tumor-related risk factors for simultaneous adrenalectomy in patients with cT1-cT2 kidney cancer during robotic assisted laparoscopic radical nephrectomy - Minerva Urology and Nephrology 2021 February;73(1):72-7 - Minerva Medica - Journals
- 1 March 2021
- Published by Edizioni Minerva Medica in Minerva Urology and Nephrology
- Vol. 73 (1) , 72-77
Identifying tumor-related risk factors for simultaneous adrenalectomy in patients with cT1-cT2 kidney cancer during robotic assisted laparoscopic radical nephrectomy
Article: Identifying tumor-related risk factors for simultaneous adrenalectomy in patients with cT1-cT2 kidney cancer during robotic assisted laparoscopic radical nephrectomy - Minerva Urology and Nephrology 2021 February;73(1):72-7 - Minerva Medica - Journals